Company’s 36-month beta value is -0.69.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy”, 1 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for BOLD is 14.94M, and currently, short sellers hold a 3.91% ratio of that floaft. The average trading volume of BOLD on July 04, 2025 was 168.91K shares.
BOLD stock’s latest price update
The stock of Boundless Bio Inc (NASDAQ: BOLD) has increased by 0.94% when compared to last closing price of $1.06. globenewswire.com reported 2025-06-05 that SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference.
BOLD’s Market Performance
Boundless Bio Inc (BOLD) has seen a 0.00% fall in stock performance for the week, with a -4.46% decline in the past month and a -28.19% plunge in the past quarter. The volatility ratio for the week is 5.37%, and the volatility levels for the past 30 days are at 6.82% for BOLD. The simple moving average for the past 20 days is 0.00% for BOLD’s stock, with a -50.99% simple moving average for the past 200 days.
Analysts’ Opinion of BOLD
Many brokerage firms have already submitted their reports for BOLD stocks, with H.C. Wainwright repeating the rating for BOLD by listing it as a “Buy”. The predicted price for BOLD in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on June 02, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see BOLD reach a price target of $3. The rating they have provided for BOLD stocks is “Market Perform” according to the report published on May 28th, 2025.
Piper Sandler gave a rating of “Overweight” to BOLD, setting the target price at $20 in the report published on April 22nd of the previous year.
BOLD Trading at -18.75% from the 50-Day Moving Average
After a stumble in the market that brought BOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.33% of loss for the given period.
Volatility was left at 6.82%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares sank -9.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.71% lower at present.
During the last 5 trading sessions, BOLD remain unchanged, which changed the moving average for the period of 200-days by -70.19% in comparison to the 20-day moving average, which settled at $1.0700. In addition, Boundless Bio Inc saw -74.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Boundless Bio Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for BOLD
The total capital return value is set at -0.4%. Equity return is now at value -54.06%, with -42.61% for asset returns.
Based on Boundless Bio Inc (BOLD), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23.
Currently, EBITDA for the company is -64.28 million with net debt to EBITDA at -0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.15.
Conclusion
In a nutshell, Boundless Bio Inc (BOLD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
